Cargando…

Atypical pattern of response in rectal cancer after neoadjuvant pembrolizumab treatment: a case report, literature review, and proposed management model

BACKGROUND: Immunotherapy is the first-line treatment in patients with advanced microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) colorectal cancer (CRC). Although immune checkpoint inhibitors (ICIs) for locally advanced rectal cancer (LARC) are not yet a standard, the resu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tissera, Natalia S., Esteso, Federico, Luca, Romina, Enrico, Diego, Waisberg, Federico, Rodriguez, Andrés, Bruno, Luisina, Kucharczyk, Mariana, Amat, Mora, García, Ximena, Pombo, Teresa, Salazar, Ivana Pedraza, Loria, Fernando Sanchez, Huertas, Eduardo, Galli, Mariana, Chacón, Matías, O’Connor, Juan Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331748/ https://www.ncbi.nlm.nih.gov/pubmed/37435212 http://dx.doi.org/10.21037/jgo-22-1140

Ejemplares similares

Implementation of a virtual multicenter gastrointestinal tumor board to reduce cancer disparities in Argentina
por: Esteso, Federico, et al.
Publicado: (2022)

Short-course radiotherapy for rectal cancer: real-world evidence in Argentina
por: Tissera, Natalia S, et al.
Publicado: (2023)

Desmoid tumour in an inguinal hernia in a patient with a previous diagnosis of melanoma
por: Tissera, Natalia, et al.
Publicado: (2022)

Official French SARS-CoV-2 guidelines for cancer patients, a triage solution with precision medicine
por: O’Connor, Juan Manuel, et al.
Publicado: (2020)

Precision medicine in the real-world setting. Clinical activity of talazoparib in a woman with hormone receptor-positive HER2-negative metastatic breast cancer with pathogenic mutation in somatic BRCA2
por: Narváez, Dana, et al.
Publicado: (2022)

Uncommon Subtypes of Malignant Melanomas: A Review Based on Clinical and Molecular Perspectives
por: Chacón, Matías, et al.
Publicado: (2020)

Quantitative Aspects of Diffusion-weighted Magnetic Resonance Imaging in Rectal Cancer Response to Neoadjuvant Therapy
por: Bassaneze, Thiago, et al.
Publicado: (2017)

Generalized Lymphatic Anomaly as a Differential Diagnosis of Lytic Lesions
por: Catani, Greta, et al.
Publicado: (2023)

Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis
por: Chacón, Matías Rodrigo, et al.
Publicado: (2018)

Implementation of a molecular tumour board in LATAM: the impact on treatment decisions for patients evaluated at Instituto Alexander Fleming, Argentina
por: Angel, Martín Osvaldo, et al.
Publicado: (2021)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
por: Enrico, Diego, et al.
Publicado: (2022)

Neoadjuvant radiotherapy for rectal cancer management
por: Feeney, Gerard, et al.
Publicado: (2019)

A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC
por: Lemmon, Christopher A., et al.
Publicado: (2022)

Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States
por: Tian, Wentao, et al.
Publicado: (2023)

Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings
por: Dobriyan, Alex, et al.
Publicado: (2021)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

Neoadjuvant Treatment in Rectal Cancer: Actual Status
por: Garajová, Ingrid, et al.
Publicado: (2011)

Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer
por: Papaccio, Federica, et al.
Publicado: (2020)

Restaging rectal cancer following neoadjuvant chemoradiotherapy
por: Cuicchi, Dajana, et al.
Publicado: (2023)

First-line cisplatin, docetaxel, and cetuximab for patients with recurrent or metastatic head and neck cancer: A multicenter cohort study
por: Falco, Agustín, et al.
Publicado: (2022)

Meta-analysis of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
por: Lin, Huaqin, et al.
Publicado: (2021)

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB–IIIB resectable lung squamous cell carcinoma
por: Shen, Dijian, et al.
Publicado: (2021)

Retraction: Tumor Microenvironment in Oral Cancer Following Neoadjuvant Pembrolizumab: Preliminary Analysis of the Histopathologic Findings
Publicado: (2022)

Combination treatment of bilateral periocular sebaceous carcinomas with microsatellite instability with neoadjuvant pembrolizumab and Mohs surgery
por: Woods, Alexander D., et al.
Publicado: (2022)

Predictive Factors of the Response of Rectal Cancer to Neoadjuvant Radiochemotherapy
por: Spolverato, Gaya, et al.
Publicado: (2011)

Neoadjuvant treatment of rectal cancer: where are we now?
por: Kalyan, Aparna, et al.
Publicado: (2016)

Total neoadjuvant treatment in locally advanced rectal cancer
por: De Felice, Francesca, et al.
Publicado: (2021)

Clinical outcome of neoadjuvant chemoradiation in rectal cancer treatment
por: Suwanthanma, Weerapat, et al.
Publicado: (2021)

Temporal determinants of tumour response to neoadjuvant rectal radiotherapy
por: Koo, Kendrick, et al.
Publicado: (2021)

Impact of neoadjuvant treatment on rectal gastrointestinal stromal tumors
por: Cheong, Chinock, et al.
Publicado: (2022)

Total neoadjuvant therapy for rectal cancer: evidence and challenge
por: Lee, Suk-Hwan
Publicado: (2023)

Resolving the tissue response to neoadjuvant chemotherapy in rectal cancer
por: Shyer, Justin A., et al.
Publicado: (2023)

Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States
por: Huang, Min, et al.
Publicado: (2023)

Outcomes in Patients Treated by Laparoscopic Resection of Rectal Carcinoma After Neoadjuvant Therapy for Rectal Cancer
por: Rezvani, Masoud, et al.
Publicado: (2007)

Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
por: George, Thomas J., et al.
Publicado: (2015)

Correlation between tumor regression grade and rectal volume in neoadjuvant concurrent chemoradiotherapy for rectal cancer
por: Lee, Hong Seok, et al.
Publicado: (2016)

The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma
por: Park, Seong Yong, et al.
Publicado: (2020)

Neoadjuvant Pembrolizumab and Chemotherapy in Resectable Esophageal Cancer: An Open-Label, Single-Arm Study (PEN-ICE)
por: Duan, Hongtao, et al.
Publicado: (2022)

Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis: Oxaliplatin in neoadjuvant treatment for rectal cancer
por: De Felice, Francesca, et al.
Publicado: (2017)

Analysis of long-term oncological results of clinical versus pathological responses after neoadjuvant treatment in locally advanced rectal cancer
por: Coraglio, Mariana F., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6u3p10872r4ckk94b1pti79lvg